Lupin wins tentative U.S. FDA approval for apixaban oral suspension
AI Summary- Lupin received tentative U.S. FDA approval for its apixaban oral suspension application.
- The formulation contains apixaban at 1.25 mg/mL and uses the 505(b)(2) pathway.
- Lupin says final approval would enable manufacturing at its Somerset, New Jersey, facility.